Cargando…

Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study

Background: An association between idiopathic pulmonary fibrosis (IPF) and advancing age is suspected since IPF occurs primarily in patients over 60 years of age. Though, little is known about the disease in the elderly. The aim of this study was to characterize elderly IPF patients using data from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leuschner, Gabriela, Klotsche, Jens, Kreuter, Michael, Prasse, Antje, Wirtz, Hubert, Pittrow, David, Frankenberger, Marion, Behr, Jürgen, Kneidinger, Nikolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703706/ https://www.ncbi.nlm.nih.gov/pubmed/33313046 http://dx.doi.org/10.3389/fmed.2020.601279

Ejemplares similares

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
por: Kreuter, Michael, et al.
Publicado: (2017)

The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
por: Kreuter, Michael, et al.
Publicado: (2019)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Mass spectrometry-based autoimmune profiling reveals predictive autoantigens in idiopathic pulmonary fibrosis
por: Leuschner, Gabriela, et al.
Publicado: (2023)

Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2023)

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial
por: Behr, Jürgen, et al.
Publicado: (2017)

Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial
por: Jarosch, Inga, et al.
Publicado: (2020)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia
por: Kirsten, Detlef, et al.
Publicado: (2021)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
por: Kaunisto, Jaana, et al.
Publicado: (2019)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
por: Krauss, Ekaterina, et al.
Publicado: (2019)

Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study
por: Veit, Tobias, et al.
Publicado: (2020)

The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)
por: Xu, Feng, et al.
Publicado: (2021)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers
por: Mayr, Christoph H, et al.
Publicado: (2021)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)
por: Colunga Biancatelli, Ruben Manuel Luciano, et al.
Publicado: (2020)

Serum Procalcitonin in Patients With Combined Lung Cancer and Idiopathic Pulmonary Fibrosis (LC-IPF)
por: Mohamed, Sherif, et al.
Publicado: (2020)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)
por: Confalonieri, Paola, et al.
Publicado: (2022)

Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine?
por: Veith, C., et al.
Publicado: (2023)

Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT)
por: Colombi, Davide, et al.
Publicado: (2015)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)
por: Boon, Kathy, et al.
Publicado: (2009)

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
por: Ferrara, Giovanni, et al.
Publicado: (2016)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
por: Cherrez-Ojeda, Iván, et al.
Publicado: (2018)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)
por: Nambiar, Shabarinath, et al.
Publicado: (2021)

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
por: Swaminathan, Aparna C., et al.
Publicado: (2022)

Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism
por: Cocconcelli, Elisabetta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_suctadvrgpjbmhksibo0clt97o